高容量血液滤过治疗脓毒症并发多器官功能障碍综合征RIFLE标准应用研究

目的探讨RIFLE标准衡量高容量血液滤过(HVHF)治疗脓毒症并发多器官功能障碍综合征(MODS)的治疗时机及其对预后的影响。方法回顾性分析成都军区总医院2006年1月至2010年12月行HVHF治疗的脓毒症并发MODS患者52例,采用RIFLE标准分A组(AKIⅠ期)、B组(AKIⅡ期)和C组(AKIⅢ期),比较各组的病死率、平均ICU住院时间、平均机械通气时间、平均连续血液滤过治疗时间,并将HVHF治疗前和治疗24 h后的APACHEⅡ评分、SOFA评分、血浆白介素(IL)-6、氧合指数、血肌酐(Scr)及平均动脉压(MAP)等指标。结果 (1)C组HVHF治疗前APACHEⅡ评分、SOFA评分、血浆IL-6及病死率均明显高于A、B组(P<0.01);(2)A、B组HVHF治疗前APACHEⅡ评分、SOFA评分及病死率比较差异无统计学意义(P>0.05),但B组HVHF治疗前IL-6及平均ICU住院时间、平均机械通气时间、平均连续血液滤过治疗时间明显高于或长于A组(P<0.01);(3)HVHF治疗24 h后血浆IL-6、氧合指数、Scr、MAP均明显改善,但C组IL-6仍高于A、B组(P<0.01),B组IL-6仍高于A组(P<0.01);A、B组HVHF治疗24 h后APACHEⅡ评分、SOFA评分显著降低(P<0.01),C组无变化(P>0.05)。结论 HVHF能有效辅助治疗脓毒症并发MODS;RIFLE标准及IL-6对判断预后有指导意义;早期(AKIⅠ期和Ⅱ期)行HVHF可明显改善脓毒症并发MODS的预后,而AKIⅠ期行HVHF的疗效更好。     

血液灌流联合连续性静脉-静脉血液滤过治疗高脂血症性胰腺炎的疗效

目的探讨血液灌流(HP)联合连续性静脉-静脉血液滤过(CVVH)技术治疗高脂血症性胰腺炎(HLP)的临床疗效。方法将19例HLP患者随机分为两组,联合治疗组10例采用HP+CVVH治疗,对照组9例采用常规CVVH治疗,比较两组治疗前后甘油三酯(TG);肿瘤坏死因子(TNF)-α、白介素(IL)-1、IL-6等细胞因子水平及急性生理与慢性健康评分(APACHE)Ⅱ和存活率。结果联合治疗组治疗7 d后TG、TNF-α、IL-1、IL-6及APACHEⅡ评分均呈下降趋势,与对照组比较差异显著(P0.05);联合治疗组存活率7/10(70%)明显高于对照组5/9(55.6%)。结论 HP联合CVVH治疗能迅速降低血脂,有效调整炎症因子水平,改善HLP患者预后,提高存活率。     

连续性血液滤过治疗重症急性胰腺炎--附13例报告

目的探讨连续性静脉-静脉血液滤过(CVVH)治疗重症急性胰腺炎(SAP)的疗效.方法13例SAP患者均接受了CVVH治疗,平均治疗时间为62 h.观察治疗前、中、后患者的血液生化指标、血常规、血气分析和细胞因子IL-1β、TNF-α、IL-6含量,并进行APACHEⅡ评分.结果13例患者中,治愈10例,死亡3例,死亡率为23.1%.CVVH治疗过程中血流动力学稳定.APACHEⅡ评分治疗前为(15.3±5.7)分,治疗后24 h、48 h及72 h分别降至(11.6±4.2)分、(9.1±3.8)分和(7.2±3.3)分,差异显著(P<0.05).CVVH治疗后12 h,血浆中细胞因子IL-1β、TNF-α、IL-6的水平均显著降低(P<0.05).结论SAP患者早期行CVVH治疗,可改善SAP预后,降低病死率.     

持续血液滤过治疗高脂血症性急性胰腺炎24例

目的:观察早期连续血液滤过(continuous veno-venous hemofiltration,CVVH)对高脂血症性急性胰腺炎(hyperlipidemic acute pancreatitis,HLP)的治疗效果.方法:49例HLP患者随机分为2组:连续血液滤过组(A组,n=24)和对照组(B组,n=25).在常规治疗的基础上,A组加用连续血液滤过.观察治疗前后两组患者的心率(HR)、呼吸(R)、氧合指数(PO2/FiO2)、血氧饱和度(SaO2)、血清甘油三酯(TG)、白介素-6(IL-6)以及肿瘤坏死因子-α(TNF-α)等指标的变化;并行APACHE~ 动态评分;比较两组治疗前后急性并发症的变化及治愈率.结果:经CVVH治疗后72h,患者临床症状改善明显,HR、R降至正常,APACHE~评分下降明显(10.8±5.1vs15.5±6.9,P<0.05);血清TG、IL-6及TNF-α亦明显下降(6.8±3.7vs18.5±6.3,39.8±16.7vs72.4±25.1,37.5±14.1vs61.2±16.1,P<0.05).治疗7d后,两组休克均获纠正(P<0.05).A组ARDS和急性肾功能障碍控制迅速,发生率下降明显(5.0%vs37.5%,5.0%vs25%,P<0.05).A组治愈22例,死亡2例,死亡率8.3%;B组治愈20例,死亡5例,死亡率20%,治疗效果显著.结论:CVVH治疗HLP有明显的效果,能有效改善患者病情,降低病死率.     

连续性血液滤过治疗重症急性胰腺炎——附13例报告

目的 探讨连续性静脉-静脉血液滤过(CVVH)治疗重症急性胰腺炎(SAP)的疗效。方法 13例SAP患者均接受了CVVH治疗,平均治疗时间为62 h。观察治疗前、中、后患者的血液生化指标、血 常规、血气分析和细胞因子IL-1β、TNF-α、IL-6含量,并进行APACHEⅡ评分。结果 13例患者中,治愈 10例,死亡3例,死亡率为23.1％。CVVH治疗过程中血流动力学稳定。APACHEⅡ评分治疗前为(15.3 ±5.7)分,治疗后24 h、48 h及72 h分别降至(11.6±4.2)分、(9.1±3.8)分和(7.2±3.3)分,差异显著 (P<0.05)。CVVH治疗后12 h。血浆中细胞因子IL-1β、TNF-α、IL-6的水平均显著降低(P<0.05)。结 论SAP患者早期行CVVH治疗,可改善SAP预后,降低病死率。     

降钙素原在连续性血液滤过治疗脓毒症患者中的应用价值

目的 探讨降钙素原(procalcitonin,PCT)在脓毒症患者血液滤过治疗中的应用价值。方法 本研究为前瞻性随机对照研究。41例重症脓毒症患者随机分为常规治疗组(对照组)和早期连续性血液净化治疗组(continuous blood purification ,CBP),入重症医学科时检测其血清降钙素原水平,并在24h、48h、96h时间点复检,并记录相应时间点的急性生理和慢性健康评分 (acute physiology and chronic health evaluation,APACHEⅡ) 和序贯器官功能衰竭评分(sequential organ failure assessment,SOFA)。比较两组间PCT水平、APACHEⅡ评分及SOFA评分的变化；比较两组患者住ICU 时间以及28d病死率。 结果 治疗前血PCT水平与APACHEⅡ评分的相关系数为0.604,存在显著的线性关系。两组患者PCT水平治疗后均明显下降,与对照组比较,CBP组患者各时间点的血PCT水平无明显差异；而24h、48h的APACHEⅡ评分和SOFA评分CBP组降低明显,差异均有统计学意义(P＜0.05)；CBP组ICU住院时间相对较短(10.89±5.80 vs 12.64±7.28,P= 0.407)、28 d病死率有降低趋势(36.8% vs 40.9%,P=1.000),但差异无统计学意义。结论 血清PCT水平与脓毒症的病情严重度存在密切相关,水平越高,提示病情越危重。高PCT水平的脓毒症尽早给予CBP治疗能减轻组织器官的损伤,有助于脓毒症的治疗。     

连续性静脉-静脉血液滤过联合血液灌流治疗严重脓毒症临床研究

目的探讨连续性静脉-静脉血液滤过(CVVH)联合血液灌流(HP)应用于严重脓毒症的临床意义。方法入选2011年12月至2014年8月收治梅州市人民医院重症医学一科的92例严重脓毒症存在血液净化治疗指征患者,随机分为CVVH组及CVVH+HP组,比较两组治疗过程中炎症介质C-反应蛋白(CRP)、补体3(C3)、内毒素;血流动力学指标平均动脉压(MAP)、中心静脉压(CVP);组织器官灌注指标血乳酸(Lac)、中心静脉血氧饱和度(Scv O2)、氧合指数(Pa O2/Fi O2);以及血小板、感染相关器官功能衰竭评分(SOFA)。结果 CVVH+HP组治疗72 h时CRP、C3及内毒素降至最低,且低于CVVH组;治疗12 h后CVVH+HP组Lac低于CVVH组(P0.05),Scv O2高于CVVH组(P0.05);MAP、CVP两组间差异无统计学意义(均P0.05);治疗24h CVVH+HP组Pa O2/Fi O2较CVVH组升高(P0.05),治疗12 h后,CVVH+HP组患者血小板水平较治疗前有所下降,且较CVVH组更低(均P0.05),治疗48h SOFA评分亦较CVVH组降低(P0.05)。结论 CVVH联合HP能够有效清除炎症介质,提高严重脓毒症患者氧合状态,改善组织器官灌注,改善器官功能,但对血小板有一定破坏。     

血液净化治疗急性中毒并发多器官功能障碍综合征82例临床观察

目的探讨血液净化治疗急性中毒并发多器官功能障碍综合征（MODS）的临床价值。方法治疗组82例在综合治疗的基础上,40例给予血液灌注（HP组）,42例用HP＋连续性静脉-静脉血液滤过（CVVH）治疗（HP＋CVVH组）。对照组86例仅给予综合治疗。结粜（1）治疗组机械通气时间（46．5±8．5）h,住院时间（10．5±3．5）d,治愈好转率91．5％（75／82）,病死率8．5％（5／82）;对照组分别为（59．5±11．5）h、（15．5±4．5）d、72．1％（62／86）及27．9％（24／86）。两组比较差异有统计学意义（P均〈0．01）。（2）HP＋CVVH组72h的肝功能、肾功能、炎性因子、APACHEⅡ评分指标比单纯HP组治疗明显改善（P均〈0．05）。（3）HP＋CVVH组的机械通气时间为（42．5±8．5）h,住院时间为（9．5±2．5）d,治愈好转率为97．6％（41／42）,病死率为2．4％（1／42）;HP组的机械通气时间为（50．5±9．5）h,住院时间为（11．5±3．5）d,治愈好转率为85．0％（34／40）,病死率为15％（6／40）,两组比较差异有统计学意义（P均〈0．05）。结论血液净化治疗急性中毒并发MODS,能从血液中直接、迅速地清除内外源性有害物质,疗效肯定,尤其HP＋CVVH治疗的疗效更为显著。     

连续性静脉静脉血液滤过治疗多器官功能障碍综合征的临床研究

目的　研究连续性静脉静脉血液滤过治疗多脏器功能衰竭的疗效。方法　1999 -12 ~2003 -12大连医科大学附属第一医院64例多器官功能障碍综合征(MODS)病人分为CVVH(静脉静脉血液滤过)治疗组34例和IHD(间歇性血液透析)治疗组30例,记录发生低血压、心律失常的次数,计算尿素清除指数(KT/V)值,治疗前后计算APACHE Ⅱ评分并记录转归情况。结果　CVVH治疗组血流动力学稳定性好于IHD治疗组;CVVH组KT/V值高于IHD组;CVVH组治疗后APACHE Ⅱ评分好于IHD组,分别为(17 .23±6 .86)分, (20. 91±5 .77)分(P<0 .05)。结论　CVVH治疗在血流动力学稳定性,溶质清除率及预后方面优于IHD。     

连续性肾脏替代治疗单用及联合血液灌流、血浆置换在高脂血症性重症急性胰腺炎的疗效评价

目的探讨连续性肾脏替代治疗(CRRT)血液灌流(HP)联合连续性静脉-静脉血液滤过治疗(HP/CVVH)、血浆置换(PE)联合连续性静脉-静脉血液滤过治疗(PE/CVVH)对高脂血症性重症急性胰腺炎(HLSAP)的治疗价值及效果评价。方法将68例HLSAP患者随机分为CVVH组、HP+CVVH组和PE+CVVH组,均予重症急性胰腺炎常规治疗,并分别予以单纯CVVH、HP+CVVH、PE+CVVH治疗。比较治疗前和治疗72 h后三组患者生命体征、APACHEⅡ评分、甘油三酯(TG)、C反应蛋白(CRP)、重要脏器功能指标变化值;CT检查评价治疗前与治疗1周后CT严重程度指数(CTSI)变化;记录治疗1周内主要并发症发生率、平均住院天数及死亡率。结果三组患者治疗前各项指标差异无显著性。但各组患者治疗后各项指标均有好转(P0.05),治疗72 h后三组间APACHEⅡ评分、血和尿淀粉酶比较差异均无统计学意义(P0.05);HP+CVVH、PE+CVVH两组与CVVH组比较其余实验室指标改善更明显(P0.05)。治疗1周后三组患者CTSI均较治疗前下降(P0.05),且HP+CVVH组和PE+CVVH组较CVVH组改善更明显(P0.05)。HP+CVVH组和PE+CVVH组较CVVH组临床情况更好,死亡率低,住院时间短(P0.05)。结论 HP、PE联合CVVH治疗较单纯CVVH治疗能够更快降低患者血TG水平,改善临床症状,可减少系统炎性反应综合征及多器官功能障碍综合征/多器官功能衰竭的发生,有效降低死亡率,减少住院时间。     

Clinical Effects of Pulse High‐Volume Hemofiltration on Severe Acute Pancreatitis Complicated With Multiple Organ Dysfunction Syndrome

To evaluate the effects of pulse high‐volume hemofiltration (PHVHF) on severe acute pancreatitis (SAP) with multiple organ dysfunction syndrome (MODS). Thirty patients were divided into two groups: PHVHF group and continuous venovenous hemofiltration (CVVH) group. They were evaluated in terms of clinical symptoms, acute physiology and chronic health evaluation (APACHE) II score, sequential organ failure assessment (SOFA) score, simplified acute physiology (SAPS) II score and biochemical changes. The levels of IL‐6, IL‐10 and TNF‐α in plasma were assessed by ELISA before and after treatment. The doses of dopamine used in shock patients were also analyzed. In the two groups, symptoms were markedly improved after treatment. Body temperature (BT), breath rate (BR), heart rate (HR), APACHE II score, SOFA score, SAPS II score, serum amylase, white blood cell count and C‐reactive protein were decreased after hemofiltration (P < 0.05). The PHVHF group was superior to the CVVH group, especially in APACHE II score, CRP (P < 0.01), HR, temperature, SOFA score and SAPS II score (P < 0.05). The doses of dopamine for shock patients were also decreased in the two groups (P < 0.05), with more reduction in the PHVHF group than the CVVH group (P < 0.05). The levels of IL‐6, IL‐10 and TNF‐α decreased (P < 0.05) in the PHVHF group more significantly than the CVVH group (P < 0.01). PHVHF appears to be superior to CVVH in the treatment of SAP with MODS.     

持续静脉-静脉血液滤过对危重症甲型H1N1流感患者呼吸功能的影响

目的 探讨持续静脉-静脉血液滤过(CVVH)对危重症甲型H1N1流感患者呼吸功能的影响.方法 通过对入选的10例甲型H1N1流感危重症患者在常规治疗的基础上联合应用CVVH治疗,分别观察干预前及干预后24 h、48 h、72 h、120 h的血清炎性介质水平[肿瘤坏死因子α(TNF-α)、白介素6(IL-6)、IL-8...     

降钙素原在体外循环心脏术后早期并发症中的预测价值研究

目的:评价血降钙素原(PCT)在体外循环心脏术后早期并发症中的预测价值。方法:126例体外循环心脏术后患者,于术后24 h检测血PCT、C反应蛋白(CRP)、IL-6、IL-8、TNF-α,并进行急性生理学与慢性健康状况(APACHEⅡ)评分及SOFA评分。按是否出现并发症分为并发症组与对照组,比较2组间各项指标是否存在差异,并将各项炎性指标与APACHEⅡ评分及SOFA评分行相关性分析。结果:并发症组56例,对照组70例。并发症组手术时间[(281±49)min vs(237±51)min]、体外循环时间[(138±35)min vs(116±39)min)]及主动脉阻断时间[(83±22)min vs(62±18)min]均显著长于对照组。并发症组PCT、IL-6、IL-8、TNF-α、APACHEⅡ评分均显著高于对照组(均P0.05),而CRP无明显差异。PCT、IL-6、IL-8、TNF-α与APACHEⅡ评分、SOFA评分均呈明显正相关,其中PCT与APACHEⅡ评分及SOFA评分相关性最高(r=0.87、0.92,P0.05)。CRP与APACHEⅡ评分及SOFA评分无相关性。结论:PCT值可作为评价体外循环心脏术后早期病情严重程度及预后的参考指标。     

Timing for Initiation of Continuous Renal Replacement Therapy in Patients With Septic Shock and Acute Kidney Injury

The optimal timing for renal replacement therapy initiation in septic acute kidney injury (AKI) remains controversial. This study investigates the impact of early versus late initiation of continuous renal replacement therapy (CRRT) on organ dysfunction among patients with septic shock and AKI. Patients were dichotomized into “early” (simplified RIFLE Risk) or “late” (simplified RIFLE Injury or Failure) CRRT initiation. Patients with chronic kidney disease stage 5 or those on long‐term dialysis were excluded. Organ dysfunction was quantified by Sequential Organ Failure Assessment (SOFA) score. From January 2008 to June 2011, 120 patients fulfilled the inclusion criteria. Thirty‐one (26%) underwent “early” while 89 (74%) had “late” CRRT. No significant difference was noted between groups on improvement of total SOFA/non‐renal SOFA score or noradrenaline equivalent in the first 24 and 48 h after CRRT initiation. Dialysis requirement and mortality (at 28 days, 3 months and 6 months) did not differ. In conclusion, improvement of non‐renal SOFA score 48 h after CRRT correlated with SOFA score on CRRT initiation (P = 0.040) and APACHE IV risk of death (P = 0.000), but not estimated glomerular filtration rate on CRRT initiation (P = 0.377). Improvement of non‐renal SOFA score correlated with SOFA score on CRRT initiation and APACHE IV risk of death. However, this retrospective review cannot identify any significant clinical benefit of early CRRT initiation in patients presenting with septic shock and AKI.     

Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration

Citrate which chelates ionized calcium can be used as regional anticoagulation in continuous venovenous hemofiltration (CVVH). This is the first study conducted to examine the potentially additive benefit effect of regional citrate anticoagulation (RCA) on polymorphonuclear (PMN) cell degranulation of myeloperoxidase (MPO) and cytokines production in patients with critically acute kidney injury (AKI) undergoing CVVH treatment. This prospective randomized controlled trial was conducted in 20 critically ill patients with AKI who underwent CVVH. The patients were randomized into regional citrate group (n=10) and heparin group (n=10). The pre-dilution CVVH with polyethersulfone dialyzers were utilized in both groups. The levels of pre-filter and post-filter MPO as well as inflammatory and anti-inflammatory cytokines were measured at baseline, 6h, and 24 h after initiating CVVH. In the heparin group, the post-filter serum MPO levels were significantly higher than the pre-filter (median 49.0 vs. 60.5 ng/mL, P<0.05) at 6 h. There were no significant differences between pre- and post-dialyzer MPO levels in the citrate group. Citrate could significantly decrease systemic pre-filter serum MPO levels from baseline at 6 h (median 43.5 vs. 17.3 ng/mL, P<0.01) as well as IL-8 levels (P<0.05) whereas heparin provided only significant TNF-α reduction (P<0.05). The CVVH circuit survival in the citrate group was longer than the heparin group. In conclusion, citrate, utilized as a regional anticoagulant in CVVH, can reduce both membrane bioincompatibility-induced and systemic oxidative stress and inflammation, and can prolong CVVH circuit survival time.     

全心舒张末期容积指数及血管外肺水指数在老年心力衰竭合并脓毒性休克患者预后中的预测价值

目的 分析全心舒张末期容积指数（GEDI）及血管外肺水指数（ELWI）在老年心力衰竭（HF）合并脓毒性休克患者中的变化情况,探究其对预后预测价值。 方法 选取海军第971医院2017年1月～2020年5月老年HF合并脓毒性休克患者87例,根据住院期间生存状况分为生存组（66例）与死亡组（21例）。比较两组一般资料、液体复苏前后GEDI与ELWI、急性生理与慢性健康评价系统Ⅱ（APACHEⅡ）、序贯脏器衰竭（SOFA）评分,采用Perason相关性分析GEDI、ELWI与APACHEⅡ、SOFA评分关联性,Logistic回归分析老年HF合并脓毒性休克患者预后相关因素,受试者工作特征（ROC）曲线评价GEDI、ELWI对预后的预测价值。 结果 两组年龄、心功能分级、合并急性呼吸窘迫综合征（ARDS）差异有统计学意义（P<0.05）;生存组液体复苏后6 h、24 h APACHEⅡ、SOFA评分、ELWI较液体复苏前降低,且显著低于死亡组,GEDI较液体复苏前升高,且显著高于死亡组（P<0.05）;Pearson相关性分析,液体复苏后6 h、24 h GEDI与APACHEⅡ、SOFA评分呈负相关,液体复苏后6 h、24 h ELWI与APACHEⅡ、SOFA评分呈正相关（P<0.05）;Logistic回归分析,年龄、心功能分级、合并ARDS、液体复苏后6 h、24 h GEDI、ELWI是老年HF合并脓毒性休克患者预后的重要影响因素（P<0.05）;ROC曲线分析,液体复苏后6 h、24 h GEDI、ELWI联合预测预后AUC分别为0.853（95%CI为0.761~0.920）、0.885（0.798~0.943）,敏感度分别为71%、81%,特异度分别为82%、86%,优于同时间点两者单独预测（P<0.05）。 结论 GEDI与ELWI可作为老年HF合并脓毒性休克患者评估病情变化与预测预后的敏感因子。     

Performance evaluation of MR-proadrenomedullin and other scoring systems in severe sepsis with pneumonia

Background

In sepsis, risk assessment is as crucial as early and accurate diagnosis. In this study, we aimed to evaluate the prognostic value of mid-regional proadrenomedullin (MR-proADM) with other scoring systems in severe sepsis and septic shock patients due to community acquired pneumonia (CAP).

Methods

Patients were divided into 2 groups as severe sepsis and septic shock due to CAP (group 1, n=31) and only CAP group (group 2, n=26). Serum MR-proADM, procalcitonin (PCT), C-reactive protein (CRP), and d-dimer level were analyzed. Acute Physiological and Chronic Health Evaluation (APACHE) II score, Sequential Organ Failure Assessment (SOFA) score, and Pneumonia Severity Index (PSI) were performed for all patients.

Results

There was no difference between groups in terms of serum MR-proADM levels (P=0.780). Serum MR-proADM was not found a significant value for the prediction of death within the 4 and 8 weeks in all patients. SOFA score was the most significant to predict mortality in 4 and 8 weeks (P<0.001). The combination of SOFA score and serum MR-proADM was a strong factor to predict death in 4 weeks (specifity 86.8% and sensitivity 66.7%). The combination of MR-proADM, SOFA score, and APACHE II score was found 75.0% sensitive and 71.4% specific to predict mortality within 4 weeks in group 1.

Conclusions

The MR-proADM does not correlate with mortality or disease severity to predict mortality. The combination of SOFA, APACHE II scores, and MR-proADM was efficient to predict prognosis and mortality rate in severe sepsis or septic shock patients.     

配对血浆滤过吸附治疗脓毒症合并多器官功能障碍综合征的临床研究

目的比较高容量血液滤过(HVHF)与配对血浆滤过吸附(CPFA)治疗脓毒症并多器官功能障碍综合征(MODS)及老年多器官功能衰竭(multiple organ failure in the elderly,MOFE)的临床疗效。方法选择脓毒症并MODS的患者14例,随机分为HVHF治疗组及CPFA治疗组,在常规治疗基础上分别予HVHF或CPFA治疗10 h,观察两种方式治疗前后的血流动力学、电解质及酸碱平衡、急性生理学及慢性健康状况评分Ⅱ(acute physiologyand chronic health evaluationⅡ,APACHEⅡ)及序贯器官衰竭估计评分(SOFA)、短期存活率等变化。结果 (1)两种治疗均能降低血尿素氮、肌酐水平,维持电解质、酸碱平衡,对白细胞、血小板、血细胞比容无明显影响。(2)CPFA治疗后氧合指数(PaO2/FiO2)明显改善(P0.05)、平均动脉压(MAP)明显升高(P0.05)、SOFA评分及APACHEⅡ评分均明显下降(P0.05);而HVHF治疗后仅见SOFA评分明显下降(P0.05),PaO2/FiO2、MAP、及APACHEⅡ评分均无明显改变(P0.05)。(3)两种方法治疗过程中均未出现出血、栓塞、过敏等并发症,老年患者耐受性好。(4)治疗7 d后HVHF组4例存活,CPFA组6例存活。结论 HVHF和CPFA治疗对脓毒症合并MODS及MOFE患者均有一定临床疗效,且后者更具优势。